Atlanta, GA, April 19, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced that it will release its financial results for the three and twelve month periods ended January 31, 2023 on Wednesday, April 26, 2023 after the close of the financial markets.
The Company will conduct a conference call on Thursday, April 27, 2023 at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast:
click here to register. You can also join by phone by dialing 877-407-8291.
A replay of the conference call will be available from Thursday, April 27, 2022 at 12:00 PM ET to Thursday, May 4, 2023 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13738301. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.
About Streamline
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net.
Company Contact
Jacob Goldberger
Director, Investor Relations and FP&A
303-887-9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.59 |
Daily Change: | -0.02 -0.55 |
Daily Volume: | 8,872 |
Market Cap: | US$15.330M |
December 18, 2024 December 16, 2024 October 08, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load